Slate Medicines
Health Care · Neurology & CNS Therapeutics
$140Mtotal raised · 2 rounds on record
$130Mlatest round · Series A · Feb 2026 · 8 mo ago
2backers · RA Capital Management, Foresite Capital
50+team · employees, estimated range
Overview
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache disorders.
Key facts
These are the key facts about Slate Medicines on Alion as of Nov 13, 2026. Slate Medicines is headquartered in Boston, United States. It was founded in 2024. It has raised $140M in 2 funding rounds. The latest round is Series A of $130M, announced in 2026.
- Headquarters
- Boston, United StatesAlion company profile, updated Oct 11, 2026
- Founded
- 2024Alion company profile, updated Oct 11, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $140MSum of 2 equity rounds Alion knows
- Latest round
- Series A · $130M · Feb 24, 2026Press report · pulse2.com
Official records
Funding and backers
Total raised
$140M
2 rounds on record
Latest round
$130M
Series A · Feb 2026 · 8 mo ago
Team
51-200
employees, estimated range
Backers
2
RA Capital Management, Foresite Capital
The money's age
Fresh money
8 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 14
New executive Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer · slatemedicines.com
Jul 16
Board appointment Slate Medicines Appoints Mark W. Hahn to Board of Directors · YahooFinance
May 18
New executive Slate Medicines Appoints John Umstead as Chief Financial Officer · slatemedicines.com
Feb 24
Raised a round Series A $130M · Pulse 2.0
2024
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Feb 2026 | $130M | — | Pulse 2.0 |
| Venture round | Feb 2026 | $10M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Slate Medicines, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Sara PachecoExecutive OfficerSEC Form D
Neil BuckleyExecutive Officer, DirectorSEC Form D
Gregory OakesExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Biomia rationally engineers nature-inspired novel small molecule therapeutics to treat CNS disorders.
Boldly advancing the next generation of medicines for Alzheimer’s Disease and Related Dementias.
Discover innovative neuropsychiatric treatments with Freedom Biosciences. Explore our pipeline of next-generation therapeutics for mental…
THE POWER OF MIGRAINE RELIEF IS ELECTRIC Relivion is the first and only wearable, at-home therapy to stimulate the 2 major nerve pathways…
Our mission is to give people with migraine a better life. As a pioneer in the field of medical devices, Salvia BioElectronics is…
People
Sara Pacheco
Executive Officer
Neil Buckley
Executive Officer, Director
Gregory Oakes
Executive Officer
Tim Lohoff
Director
Cindy Xiong
Director
Andrew Levin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Foresite CapitalVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
RALEIGH, N.C. - Slate Medicines Inc. ("Slate"), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache dis
Read more
Report
Slate Medicines Announces First Participant Dosed in Phase 1 Study Evaluating SLTE-1009
Phase 1 single- and multiple-ascending dose study in healthy volunteers evaluating the pharmacokinetics and safety of SLTE-1009; Topline safety and pharmacokinetic data expected mid-2027 RALEIGH, N.C. - Slate Medicines Inc., ("Slate"), a clinical stage bi
Read more
Report
Fulcrum Therapeutics And Slate Medicines To Merge With $245 Million Financing And Estimated $270 Million Fulcrum Dividend
Fulcrum Therapeutics and Slate Medicines have entered into a definitive all-stock merger agreement that will create a Nasdaq-listed biotechnology company focused on next-generation migraine treatments and backed by an oversubscribed $245 million private p
Read more
Report
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate's lead product candidate, SLTE-1009, is a clinical stage, potentially best-in-class subcutaneous anti-PACAP/VIP monoclon
Read more
Report
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
--Fulcrum Therapeutics, Inc. and Slate Medicines, Inc., a biotechnology company developing next-generation therapeutics for the treatment of migraine, announced today that they have entered into a definitive agreement to combine the companies in an all-st
Read more
Report
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
Leading neurologists and researchers to provide strategic and clinical guidance as Slate Medicines progresses SLTE-1009 and a broader pipeline of migraine therapeutics.
Read more
Report
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
Leading neurologists and researchers to provide strategic and clinical guidance as Slate Medicines progresses SLTE-1009 and a broader pipeline of migraine therapeutics. RALEIGH, N.C. - Slate Medicines, a privately-held biotech company advancing next-gener
Read more
Report
Slate Medicines Appoints Mark W. Hahn to Board of Directors
By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life scie
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Boston
United States
HQ
50-200 est. staff
How to cite this page
Alion, "Slate Medicines: key facts", as of Nov 13, 2026. https://alion.io/company/slatemedicines
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0